CLEVELAND, July 14 10, 2022 (GLOBE NEWSWIRE) — SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in the treatment of chronic pain will be presented at the American Society of Pain & Neuroscience ( FNHA ) conference July 14-17.
will be the subject of an oral presentation by Dr. Chris Gilmore of the Carolinas Pain Institute on Saturday, July 16. clinically significant improvement one year after 60-day treatment. There were no serious or unexpected adverse events during this study, and the most common adverse events were mild skin irritation or pruritus (itching). This work was selected as one of 25 oral presentations for the conference from a pool of over 160 submissions based on assessments by a panel of reviewers as part of the scientific review committee of the ASPN.
represents one of the largest studies in the PNS with nearly 4,500 patients evaluated retrospectively. Positive response to SPRINT PNS was consistent across a wide range of nerve targets, with 72% of patients defined as responders at the end of 60-day treatment based on pain relief and/or quality improvement of life. Although safety data were not included in this review, previously published studies found that the most common adverse events included skin irritation from bandages or adhesives and discomfort from the procedure of probe placement.
“These studies continue to corroborate and support the positive results we have seen in many clinical and real-world use cases of SPRINT PNS throughout the body with high consistency,” said Josh Boggs, PhD, Chief Scientific Officer at SPR Therapeutics.
About the SPRINT® PNS System The SPRINT® PNS System, from SPR® Therapeutics, marks an innovative evolution in the treatment of pain. Our revolutionary 60-day treatment is an SNP First-Line™ option specifically designed to recondition the central nervous system to provide significant, long-lasting relief from chronic pain – without permanent implants, nerve destruction or the risk of addiction. The system has been extensively studied for lower back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and is cleared for use for up to 60 days. Recognized by leading pain management centers, the breakthrough neuromodulation treatment offers a patient-preferred alternative to more invasive options.
The SPRINT PNS System is indicated for up to 60 days for: symptomatic relief of intractable chronic pain, acute post-surgical and post-traumatic pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to treat pain in the area innervated by the cranial and facial nerves.
Physicians should use good judgment when deciding when to use the SPRINT PNS System. For more information, see the SPRINT PNS System Instructions for Use. The most common adverse events are skin irritation and erythema. Results may vary. Rx only.
For more information on safety and effectiveness, visit www.SprintPNS.com.
About SPR Therapeutics, Inc. SPR Therapeutics is a privately held medical device company providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System addresses a critical unmet need for a drug-free, surgery-free option for millions of chronic pain sufferers. Backed by the largest body of clinical evidence, SPR has demonstrated commercial demand in the untapped peripheral pain (shoulder and knee) and back pain markets and has built an incredibly strong foundation for commercial growth. Based in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s leadership team includes experienced industry veterans with nearly 200 years of collective expertise in the pain market and medical technologies, all driven by our goal – to improve the quality of patients’ by providing them with a minimally invasive, drug-free and surgery-free solution to manage their acute and chronic pain.
More information can be found at www.SPRTherapeutics.com.